PULMOTECH™ MAA

(kit for the preparation of technetium Tc 99m albumin aggregated) injection

Offering flexibility and value

Pulmotech MAA meets your challenges with:

- Competitive and versatile pricing
- Multiple packaging options
- Renowned distribution network

Indications and Usage

PULMOTECH MAA, after radiolabeling with technetium-99m, is indicated for:

- Lung scintigraphy as an adjunct in the evaluation of pulmonary perfusion in adults and pediatric patients.
- Peritoneovenous shunt scintigraphy as an aid in the evaluation of its patency in adults.

IMPORTANT RISK INFORMATION

CONTRAINDICATIONS

PULMOTECH MAA is contraindicated in patients with:

- Severe pulmonary hypertension.
- A history of hypersensitivity to albumin human. Reactions have included anaphylaxis.

Please see additional Important Risk Information throughout and on back. Please see accompanying full Prescribing Information.

Not all MAA products are the same

DRAXIMAGE MAA[1]		PULMOTECH MAA[2]	
✓	Dosed as an MAA imaging agent	✓	
✓	Indicated for pulmonary perfusion scans	✓	
✓	Prior to radiolabeling, store at 2° to 25 °C (36° to 77 °F)	✓	
✓	Prepared by a nuclear pharmacy	✓	
✓	Uses HCPCS code A9540[3]	✓	
✗	Flexible pricing offered	✓	*The lower the particle count, the lower the price.*
✗	Vial packaging options available	✓	*Purchase a quantity that's suitable for your storage and scheduling needs.*
✗	BUD of up to 18 hours	✓	*Longer BUD gives you an extended period to administer Pulmotech MAA.*
✗	Vial volume >10 mL	✓	*Potential for more dilution.*
✗	Activity aligned with particle needs	✓	*Potential to reduce cost and waste.*

Abbreviations: MAA, macroaggregated albumin; HCPCS, Healthcare Common Procedure Coding System; BUD, beyond use date.

IMPORTANT RISK INFORMATION

WARNINGS AND PRECAUTIONS

Pulmonary Hypertension: Administer the lowest number of particles possible, have emergency resuscitation equipment available, and monitor patients for adverse reactions.

Hypersensitivity Reactions: Have emergency resuscitation equipment and trained personnel available prior to administration of Technetium Tc 99m Albumin Aggregated Injection. Interrupt the administration if a reaction occurs during administration. Monitor patients.

Broaden your diagnostic choices with Pulmotech MAA



DEPENDING ON WHAT IS IN STOCK



5 VIAL CLAM SHELL

30 VIAL CARTON[2]

15-mL VIALS INCLUDED WILL FIT IN A 10-mL SHIELD

VERSATILE PRICING AND PACKAGING POTENTIALLY RESULT IN REDUCED COST AND WASTE

18-HOUR BUD PROLONGS ADMINISTRATION WINDOW AND ALLOWS FOR FLEXIBLE PATIENT SCHEDULING[2]

Pulmotech MAA produces quality diagnostic images

Within 1 to 5 minutes of intravenous injection, more than 90% of Pulmotech MAA particles are trapped in the arterioles and capillaries of the lung.[2]

References: 1. DraxImage MAA. Prescribing information. Jubilant DraxImage Inc; December 2023. **2.** Pulmotech MAA. Prescribing information. Curium US LLC; August 2023. **3.** 2024 HCPCS Code A9540. HCPCS Data website. 2024. Accessed January 16, 2024. https://www.hcpcsdata.com/Codes/A/A9540

IMPORTANT RISK INFORMATION

WARNINGS AND PRECAUTIONS, CONTINUED

Risk of Temporary Impediment to Blood Flow in Patients with Right-to-Left Heart Shunts: Administer the lowest possible number of particles of Technetium Tc 99m Albumin Aggregated Injection.

Please see additional Important Risk Information throughout and on back. Please see accompanying full Prescribing Information.

PULMOTECH™ MAA

(kit for the preparation of technetium Tc 99m albumin aggregated) injection

Pulmotech MAA: Offering flexibility and value

When diagnosing pulmonary embolism, it's time we zeroed in on the potential to cut cost and waste without sacrificing quality.

Pulmotech MAA gives you:

- Competitive and versatile pricing
- Multiple packaging options
- Renowned distribution network

Contact your Curium representative or call customer service at 888-744-1414, Monday through Friday, 7 AM to 5 PM CT.

Indications and Usage

PULMOTECH MAA, after radiolabeling with technetium-99m, is indicated for:

- Lung scintigraphy as an adjunct in the evaluation of pulmonary perfusion in adults and pediatric patients.
- Peritoneovenous shunt scintigraphy as an aid in the evaluation of its patency in adults.

IMPORTANT RISK INFORMATION

CONTRAINDICATIONS

PULMOTECH MAA is contraindicated in patients with:

- Severe pulmonary hypertension.
- A history of hypersensitivity to albumin human. Reactions have included anaphylaxis.

WARNINGS AND PRECAUTIONS

Pulmonary Hypertension: Administer the lowest number of particles possible, have emergency resuscitation equipment available, and monitor patients for adverse reactions.

Hypersensitivity Reactions: Have emergency resuscitation equipment and trained personnel available prior to administration of Technetium Tc 99m Albumin Aggregated Injection. Interrupt the administration if a reaction occurs during administration. Monitor patients.

Risk of Temporary Impediment to Blood Flow in Patients with Right-to-Left Heart Shunts: Administer the lowest possible number of particles of Technetium Tc 99m Albumin Aggregated Injection.

Radiation Risks: Long-term cumulative radiation exposure is associated with an increased risk for cancer. Ensure safe handling to minimize radiation exposure to the patient and health care providers. Advise patients to hydrate before and after administration and to void frequently after administration.

ADVERSE REACTIONS

The following adverse reactions have been reported: Death in patients with severe pulmonary hypertension, anaphylaxis, impairment of cardiac and circulatory functions in the form of changes in respiration, pulse, blood pressure, chest pain, possible syncope, urticaria, reddening of the face, sweating, nausea, and injection site reaction.

Use in Specific Populations

Lactation: Temporarily discontinue breastfeeding and pump and discard breast milk for a minimum of at least 24 hours after administration of Technetium Tc 99m Albumin Aggregated Injection.

Pregnancy: Available data from case reports on Technetium Tc 99m Albumin Aggregated Injection use are insufficient to evaluate drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Although all radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose, the radiation exposure to the fetus from technetium Tc 99m albumin aggregated is expected to be low (less than 0.50 mGy).

CURIUM™

PULMOTECH™ MAA

(kit for the preparation of technetium Tc 99m albumin aggregated) injection